Lumos Pharma, Inc. (LUMO) |
| 4.34 0 (0%) 12-11 16:00 |
| Open: | 4.33 |
| High: | 4.34 |
| Low: | 4.33 |
| Volume: | 390,873 |
| Market Cap: | 38(M) |
| PE Ratio: | -1.01 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.44 |
| Resistance 1: | 4.37 |
| Pivot price: | 4.33 |
| Support 1: | 4.25 |
| Support 2: | 3.54 |
| 52w High: | 4.5756 |
| 52w Low: | 1.3701 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Financials
| EPS | 0.000 |
| Book Value | -4.280 |
| PEG Ratio | 0.00 |
| Gross Profit | -20.556 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -1.00 |
| Return on Assets (ttm) | 52.3 |
| Return on Equity (ttm) | -69.6 |
Company news
Thu, 12 Dec 2024
Lumos Pharma Completes Merger and Delisting Process - Nasdaq
Thu, 12 Dec 2024
Lumos Pharma Closes $38M Acquisition Deal with Double Point Ventures, Offers Premium Plus CVR Rights - Stock Titan
Thu, 12 Dec 2024
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma - Yahoo Finance
Tue, 20 Apr 2021
Lumos Pharma Names Lori Lawley CFO - citybiz
Tue, 15 Dec 2020
What You Need To Know About Lumos Pharma, Inc.'s (NASDAQ:LUMO) Investor Composition - Yahoo Finance
Wed, 27 May 2020
Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
